Drugs / Reproxalap
Reproxalap
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Rejected (CRL) | US (FDA) | — | dry eye syndrome | 2026-03-17 | “receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) of reproxalap” aldeyra.com ↗ |
| Filed | US (FDA) | — | dry eye syndrome | 2025-06-17 | “today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap” aldeyra.com ↗ |
| Rejected (CRL) | US (FDA) | — | dry eye syndrome | 2025-04-03 | “receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of reproxalap” aldeyra.com ↗ |
| Filed | US (FDA) | — | dry eye syndrome | 2024-10-03 | “today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap” aldeyra.com ↗ |
| Rejected (CRL) | US (FDA) | — | dry eye syndrome | 2023-11-27 | “receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) of reproxalap” aldeyra.com ↗ |
Trials 22
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06826196 | Mar 2025 → Oct 2026 expected | alopecia areata | Aldena Therapeutics | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03709121 | Oct 2018 → Mar 2019 | atopic conjunctivitis | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03660878 | Sep 2018 → Nov 2019 | conjunctivitis | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT05424549 | Mar → May 2022 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05102409 | Sep → Oct 2021 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04971031 | Jun → Sep 2021 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03916042 | Apr → Nov 2019 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03404115 | Jan → Jul 2018 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03162783 | May → Jul 2017 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03012165 | Dec 2016 → May 2017 | conjunctivitis | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02406209 | Mar 2015 → Apr 2016 | non-infectious anterior uveitis | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT04674358 | Nov 2020 → Sep 2021 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | Missed primary |
| Phase 310 trials · 3 met primary · 1 missed | ||||||
| Phase 3 | NCT06493604 | Jun 2024 → Feb 2025 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT06424444 | Apr → Nov 2024 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT06389214 | Apr → Jun 2024 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05234554 | Jan 2022 → Apr 2023 | conjunctivitis | Aldeyra Therapeutics, Inc. | Completed | Met primary |
| Phase 3 | NCT05062330 | Aug 2021 → Mar 2022 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | Met primary |
| Phase 3 | NCT04735393 | Jan 2021 → Oct 2022 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03879863 | Apr → Oct 2019 | dry eye syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03445650 | Jul 2018 → Jan 2020 | Sjogren-Larsson syndrome | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03494504 | Mar → Nov 2018 | conjunctivitis | Aldeyra Therapeutics, Inc. | Completed | Met primary |
| Phase 3 | NCT03131154 | Apr 2017 → Apr 2019 | non-infectious anterior uveitis | Aldeyra Therapeutics, Inc. | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04207736 Comparator | Dec 2019 → Feb 2021 | eye allergy | Aldeyra Therapeutics, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 43
| Date | Issuer | Release |
|---|---|---|
| 2026-03-17 | Aldeyra Therapeutics, Inc. | Regulatory Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease aldeyra.com ↗
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. |
| 2025-12-15 | Aldeyra Therapeutics, Inc. | Regulatory Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease aldeyra.com ↗
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for the reproxalap New Drug Application (NDA) for the treatment of dry eye disease. |
| 2025-07-17 | Aldeyra Therapeutics, Inc. | Regulatory Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease aldeyra.com ↗ |
| 2025-06-17 | Aldeyra Therapeutics, Inc. | Regulatory Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease aldeyra.com ↗
today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap |
| 2025-05-05 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission aldeyra.com ↗
In a Dry Eye Chamber Trial, Reproxalap Was Statistically Superior (P=0.002) to Vehicle in Primary Endpoint of Ocular Discomfort |
| 2025-04-03 | Aldeyra Therapeutics, Inc. | Regulatory Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease aldeyra.com ↗ |
| 2024-11-18 | Aldeyra Therapeutics, Inc. | Regulatory Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement aldeyra.com ↗ |
| 2024-10-03 | Aldeyra Therapeutics, Inc. | Regulatory Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease aldeyra.com ↗
today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. |
| 2024-08-08 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap aldeyra.com ↗
Reproxalap was statistically superior to vehicle for the prespecified primary endpoint of ocular discomfort (P=0.004), a U.S. Food and Drug Administration (FDA)-accepted symptom of dry eye disease. |
| 2023-11-27 | Aldeyra Therapeutics, Inc. | Regulatory Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease aldeyra.com ↗
the FDA stated in the letter that the NDA did not demonstrate “efficacy in treating ocular symptoms associated with dry eyes” |
| 2023-06-15 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE‑2 Trial of Reproxalap in Allergic Conjunctivitis aldeyra.com ↗
The clinical trial successfully achieved statistical significance for the primary endpoint and all secondary endpoints. |
| 2023-02-28 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease aldeyra.com ↗
The primary endpoints of treatment-related serious adverse events in ocular safety were not observed in any patient. |
| 2023-02-07 | Aldeyra Therapeutics, Inc. | Regulatory Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease aldeyra.com ↗ |
| 2022-11-29 | Aldeyra Therapeutics, Inc. | Regulatory Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease aldeyra.com ↗
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. |
| 2022-10-26 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting aldeyra.com ↗
“Reproxalap demonstrated statistically significant and clinically relevant reductions relative to vehicle in ocular itching and redness in the INVIGORATE Trial,” Dr. Lang stated. |
| 2022-07-12 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial aldeyra.com ↗
Reproxalap was statistically superior to vehicle for each of the two prespecified primary endpoints, ocular redness in a dry eye chamber (P=0.0004) and Schirmer test (P=0.0005), a measure of tear production, after a single day of dosing. |
| 2022-06-08 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY‑2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease aldeyra.com ↗
Reproxalap was statistically superior to vehicle for each of the two prespecified primary endpoints, Schirmer test (p=0.0001) and ≥10 mm Schirmer test responder proportions (p<0.0001) after a single day of dosing. |
| 2022-05-18 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness aldeyra.com ↗
Post-Hoc Analysis Using Computer Automated Grading Indicated that Reproxalap is Statistically Superior to Vehicle (p=0.020) in Reducing Dry-Eye Associated Ocular Redness, the Primary Endpoint of Phase 3 TRANQUILITY Trial |
| 2022-02-01 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Model aldeyra.com ↗ |
| 2022-01-11 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra® aldeyra.com ↗
Patient-reported ocular discomfort (p=0.002) and itching (p=0.01) were statistically lower with reproxalap than with Xiidra. |
| 2021-12-20 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Announces Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye Disease aldeyra.com ↗
Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. |
| 2021-11-02 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double-Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye Disease aldeyra.com ↗
Ocular redness scores in the reproxalap group were observed to be statistically lower than those of vehicle (p = 0.016). |
| 2021-04-27 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis aldeyra.com ↗
The clinical trial successfully achieved statistical significance for the primary endpoint and all secondary endpoints. |
| 2021-01-07 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease aldeyra.com ↗
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced positive top-line symptom, redness, and Schirmer’s test results from the run-in cohort of the Phase 3 TRANQUILITY clinical trial in patients with dry eye disease. |
| 2020-10-22 | Aldeyra Therapeutics, Inc. | Results Aldeyra to Present New Reproxalap Data from Phase 2 Clinical Trial in Allergic Conjunctivitis at American Academy of Ophthalmology 2020 Annual Meeting aldeyra.com ↗
In addition, time-to-event responder analyses demonstrated the clinical relevance of the superiority of reproxalap over vehicle for ocular itching and ocular redness. |
| 2020-06-04 | Aldeyra Therapeutics, Inc. | Regulatory Aldeyra Therapeutics Reaches Agreement with the US Food and Drug Administration for the Use of RASP as an Objective Sign for the Treatment of Dry Eye Disease aldeyra.com ↗
agreement has been reached with the US Food and Drug Administration (FDA) for the use of RASP (reactive aldehyde species) as an objective sign for the treatment of dry eye disease. |
| 2020-02-24 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Day aldeyra.com ↗
Aldeyra will announce that the Phase 2 novel formulation clinical trial in dry eye disease achieved the primary endpoint of symptom control. |
| 2019-12-03 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Announces Positive Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease aldeyra.com ↗
Primary objective of RENEW Part 1 achieved: Induction-maintenance dosing regimen of topical ocular reproxalap advanced to RENEW Part 2 |
| 2019-10-31 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Releases Expanded Results from Allergen Chamber Trial and Announces Plans to Initiate the Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis aldeyra.com ↗
The expanded results from our allergen chamber trial demonstrate highly statistically significant activity of reproxalap relative to vehicle across all assessed symptoms and signs, |
| 2019-09-26 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics to Present Phase 3 ALLEVIATE Trial Results in Allergic Conjunctivitis at American Academy of Ophthalmology 2019 Annual Meeting aldeyra.com ↗
The trial achieved the primary endpoint of reduction in patient-reported ocular itching relative to vehicle, as assessed by area under the ocular itch score curve. |
| 2019-06-25 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Announces Results from the SOLACE Trial in Noninfectious Anterior Uveitis aldeyra.com ↗
Statistical significance was not achieved for the primary or secondary endpoints, due to high rates of disease resolution in vehicle-treated patients, but activity of reproxalap was consistently greater than that of vehicle. |
| 2019-04-09 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Announces Presentation of Phase 2b Dry Eye Disease Results at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting aldeyra.com ↗
Results from a Phase 2b clinical trial completed in 2018 demonstrated that reproxalap was statistically superior to vehicle across multiple dry eye disease symptoms and signs. |
| 2019-03-26 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis aldeyra.com ↗
The clinical trial met the primary endpoint and the key secondary endpoint for both concentrations of reproxalap. |
| 2018-09-26 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Announces Positive Results from Phase 2b Dry Eye Disease Clinical Trial aldeyra.com ↗
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced positive results from its Phase 2b clinical trial of topical ocular reproxalap in patients with dry eye disease. |
| 2018-05-01 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at the Association for Research in Vision and Ophthalmology 2018 Annual Meeting aldeyra.com ↗
Tear levels of pro -inflammatory reactive aldehyde species (RASP), which are sequestered by reproxalap, were significantly decreased following treatment. |
| 2017-11-29 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data to the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting aldeyra.com ↗
The results of the analyses demonstrated formal statistical non -inferiority (p=0.036 after two weeks of therapy, p=0.048 after four weeks of therapy) of 0.5% reproxalap ophthalmic solution to Pred Forte ®, a topical ocular corticosteroid, in reducing anterior chamber inflammatory cell count, the standard noninfectious anterior uveitis clinical endpoint. |
| 2017-11-09 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Announces Third Quarter 2017 Financial Results aldeyra.com ↗
Announced New Results from Phase 2b Allergic Conjunctivitis Clinical Trial Demonstrating Clinically Relevant Activity of Reproxalap. |
| 2017-10-10 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Announces New Data at 2017 Research & Development Day aldeyra.com ↗
Newly announced results from the recent Phase 2a clinical trial in dry eye disease indicated that the statistically significant reduction in levels of a pro -inflammatory aldehyde mediator, malondialdehyde, was correlated with improvement of ocular staining scores and tear osmolarity. |
| 2017-09-12 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Announces Positive Results from Dry Eye Disease Phase 2a Clinical Trial aldeyra.com ↗
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced positive results from a Phase 2a clinical trial of topical ocular ADX -102 in patients with dry eye disease. |
| 2017-06-14 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Announces Results from Allergic Conjunctivitis Phase 2b Clinical Trial and Plans for Phase 3 Clinical Testing aldeyra.com ↗
One-Point Reduction vs. Control Component of Primary Endpoint Not Met but 0.5% ADX-102 Statistically Superior to Control and Demonstrates Late-Phase Anti-Inflammatory Activity Differentiated from Standard of Care |
| 2017-05-17 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data at the Association for Research in Vision and Ophthalmology 2017 Annual Meeting aldeyra.com ↗
Data from the trial demonstrated ADX-102 activity comparable to standard -of-care topical ocular corticosteroids in reducing anterior chamber cell count in patients with active noninfectious anterior uveitis (NAU). |
| 2017-04-20 | Aldeyra Therapeutics, Inc. | Regulatory Aldeyra Therapeutics, Inc. Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-102 in Sjögren-Larsson Syndrome aldeyra.com ↗
today announced that the United States Food and Drug Administration (FDA) has granted Aldeyra's novel compound ADX -102 orphan drug designation for the treatment of congenital ichthyosis, a severe skin disease characteristic of Sjögren -Larsson Syndrome (SLS). |
| 2016-11-07 | Aldeyra Therapeutics, Inc. | Results Aldeyra Therapeutics Announces Presentation of Phase 2 Allergic Conjunctivitis Results at the 2016 American College of Allergy, Asthma and Immunology Annual Scientific Meeting aldeyra.com ↗
The data represent the first demonstration of the clinical efficacy of aldehyde trapping in human disease, and support the continued development of ADX-102 in allergic conjunctivitis and other inflammatory diseases. |
All press releases naming this drug 57 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | reproxalap | “This clinical trial assessed the activity of reproxalap, a novel reactive aldehyde species modulator, and estimated clinically relevant thresholds for changes in ocular itching...” PMID 35585427 ↗ May 202220“Randomized Phase 2 Trial of Reproxalap, a Novel Reactive Aldehyde Species Inhibitor, in Patients with Noninfectious Anterior Uveitis: Model for Corticosteroid Replacement.” PMID 32955967 ↗ Sep 2020 “The results suggest that the novel RASP inhibitor reproxalap has the potential to mitigate the signs and symptoms of DED” PMID 33450164 ↗ Jan 2021 |
| Known as | ADX-102 | “ADX-102 1% Topical Dermal Cream (reproxalap)” NCT03445650 ↗ |
| Known as | ALD-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06826196 ↗ |
| Action | Inhibit | “reproxalap, a novel inhibitor of reactive aldehyde species (RASP), for the treatment of ocular inflammation” PMID 32955967 ↗ Sep 2020 |
| Modality | Other / unclassified | “Reproxalap, a novel reactive aldehyde species modulator” PMID 35585427 ↗ May 2022 |
| Route | Topical | “reproxalap 0.5% ophthalmic solution (4 times daily for 6 weeks)” PMID 32955967 ↗ Sep 2020 |